Which Manufacturers and Drugs Are in the 340B Rebate Pilot

The 10 approved manufacturers and their drugs

HRSA has approved rebate plans from 10 manufacturers. Every plan starts January 1, 2027, and every plan uses Beacon.

New to the pilot? Our explainer on HRSA's revised rebate model covers the dates and the claim process.

Check the NDC-11, not just the brand name

A brand name is only a starting point. Each manufacturer's plan lists the exact 11-digit NDCs that move to rebates, and any package not on that list keeps the upfront 340B price. The NDC lists are in each manufacturer's plan on HRSA's pilot page and on the Beacon resources page. HRSA's site governs legal scope, while Beacon's page tends to show implementation details first, and the two are not always worded the same way.

Negotiated drugs that keep upfront 340B pricing

Being on Medicare's negotiated price list does not automatically put a drug in the pilot. These drugs keep the upfront 340B price in 2027:

• Ozempic, Rybelsus and Wegovy (Novo Nordisk): on the 2027 negotiated price list, but Novo Nordisk did not submit a rebate plan.
• Calquence (AstraZeneca): on the 2027 list, but AstraZeneca's plan covers Farxiga only.
• Xifaxan (Bausch Health): on the 2027 list, with no HRSA-approved rebate plan.
• Entresto, Stelara, Xarelto, NovoLog and Fiasp: CMS removed them from Medicare price negotiation starting January 1, 2027, after generic or biosimilar competition.

This matters more than it looks. In Aventi's analysis of its client portfolio, Ozempic was easily the highest-volume drug on the 2027 negotiated list, and it stays on the upfront model.

How the list could change

Manufacturers need HRSA approval before changing a plan, and HRSA decides whether a change requires notice to covered entities. If CMS adds a new NDC to its selected drug list, the manufacturer must notify HRSA before including it. Rebates cannot be offered on NDCs that are not on the CMS list.

Start with your own claims

Pull last year's claims for these drugs and see how much of your program they represent. For some covered entities the share is small. For others it is a meaningful part of their 340B savings. Then keep one reference list of pilot NDCs and recheck it every quarter.

Where Aventi fits

Aventi flags pilot NDCs automatically and routes them to the rebate workflow, while non-pilot drugs stay on the normal replenishment path. A free 340B assessment shows you exactly which of your claims fall into the pilot.